An open label, dose-finding and proof of concept study of the PD-L1 Probody™ therapeutic, CX-072, as monotherapy and in combination with Yervoy® (ipilimumab) or with Zelboraf® (vemurafenib) in subjects with advanced or recurrent solid tumors or lymphomas
A phase 1-2, open-label, dose-finding, proof of concept, first-in-human study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of CX-2009 in adults with metastatic or locally advanced unresectable solid tumors.
A randomized phase III trial for surgically resected early stage non-small cell lung cancer: Crizotinib versus observation for patients with tumors harboring the anaplastic lymphoma kinase (ALK) fusion protein.
Phase II multi-center study of pembrolizumab in combination with platinum-based doublet chemotherapy in patients with EGFR mutation and ALK positive non-small cell lung cancer with progressive disease following prior tyrosine kinase inhibitors (TKIs).
A randomized two arm phase II trial of pembrolizumab alone or sequentially following single fraction non-ablative radiation to one of the target lesions, in previously treated patients with stage IV NSCLC.